ライフサイエンスコーパス: hemorrhagic

1 those with prior ischemic (-76% and -41%) or hemorrhagic (-81% and 67%) stroke and prior bleeding (-8

2 Moreover, hemorrhagic but not non-hemorrhagic Acer2-deficient placentas exhibit an expansi

3 Seven loci influenced both hemorrhagic and ischemic stroke, 3 of which influenced i

4 However, overlap exists between hemorrhagic and ischemic stroke, which may reflect share

5 study outcome of hospitalization for stroke (hemorrhagic and ischemic) or hospitalization for major h

6 The occurrence of stroke of any type (hemorrhagic and ischemic) or of any functional severity

7 l sinus DAVFs were included and divided into hemorrhagic and nonhemorrhagic groups based on initial p

8 the efficacy (thrombotic events) and safety (hemorrhagic and other adverse events and graft outcomes)

9 tcomes were anti-factor Xa, the incidence of hemorrhagic and thrombotic events, and the amount of blo

10 ), 128294 from stroke (16125 ischemic, 32591 hemorrhagic, and 79578 other), and 67914 from type 2 dia

11 Hemorrhagic arteriovenous malformations and cavernous ma

12 fever was 46.0% and 77.0% respectively, for hemorrhagic bullae 25.2% and 95.8%, and for hypotension

13 Moreover, hemorrhagic but not non-hemorrhagic Acer2-deficient plac

14 ricted to UHCA, but also encompassed certain hemorrhagic cases in other HCA subtypes, particularly IH

15 otal Sequential Organ Failure Assessment for hemorrhagic causes (area under the curve, 0.75; standard

16 perative recognition of hardly removable old hemorrhagic clot as self-blockage site of posterior scle

17 the molecular basis of antibiotic-associated hemorrhagic colitis (AAHC) caused by intestinal resident

18 of large outbreaks worldwide associated with hemorrhagic colitis and hemolytic uremic syndrome.

19 ociated with severe disease outcomes such as hemorrhagic colitis and hemolytic uremic syndrome.

20 an pathogen that causes disease ranging from hemorrhagic colitis to hemolytic uremic syndrome.

21 dural BP characteristics and recanalization, hemorrhagic complications and outcome in patients receiv

22 Thrombotic and hemorrhagic complications are prevalent in patients with

23 pplied to predict severe maternal outcome in hemorrhagic complications.

24 erapy is often refrained from out of fear of hemorrhagic complications.

25 ulopathy characterized by thromboembolic and hemorrhagic complications.

26 BackgroundTraumatic hemorrhagic contusions are associated with iodine leak;

27 virus (BKPyV) is associated with symptomatic hemorrhagic cystitis after hematopoietic cell transplant

28 Cyclophosphamide may cause hemorrhagic cystitis and eventually bladder urothelial c

29 nephropathy in renal transplant patients and hemorrhagic cystitis in bone marrow transplant patients.

30 2 or its ligands may have increased risks of hemorrhagic cystitis or urothelial cancer from persisten

31 de and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications c

32 cally targeted to prevent ifosfamide-induced hemorrhagic cystitis.

33 Bluetongue virus and epizootic hemorrhagic disease (HD) virus are globally distributed,

34 Rabbit hemorrhagic disease (RHD) is a veterinary disease that a

35 e findings expand our understanding of viral hemorrhagic disease and associated coagulopathy and sugg

36 t numbers, due to the introduction of rabbit hemorrhagic disease and prolonged drought in southeaster

37 Yellow fever (YF) is a vector-borne viral hemorrhagic disease endemic in Africa and Latin America.

38 EBOV) has caused numerous outbreaks of fatal hemorrhagic disease in Africa.

39 ld mammarenaviruses (NWMs) that causes fatal hemorrhagic disease in humans and is the etiological age

40 Arenaviruses cause fatal hemorrhagic disease in humans.

41 iotropic herpesvirus (EEHV) can cause lethal hemorrhagic disease in juvenile Asian elephants, both in

42 an insect-borne, double-capsid virus causing hemorrhagic disease in livestock around the world.

43 any parts of the world, often causing severe hemorrhagic disease in livestock.

44 ily, is a nonenveloped arbovirus that causes hemorrhagic disease in ruminants.

45 can swine fever virus (ASFV) causes a lethal hemorrhagic disease of domestic pigs, against which no v

46 sults showed that elephants dying from EEHV1 hemorrhagic disease or ill from EEHV infection were sero

47 usative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa.

48 In Portugal, rabbit hemorrhagic disease virus (RHDV) was reported in 1989 an

49 as known mammalian pathogens such as rabbit hemorrhagic disease virus 2.

50 eclined following the introduction of rabbit hemorrhagic disease virus and drought in the geographic

51 iridae family (mouse norovirus [MNV], rabbit hemorrhagic disease virus, and human norovirus genotype

52 rus similar to Ebola virus and also causes a hemorrhagic disease which is highly lethal.

53 to Ebola virus (EBOV) associated with human hemorrhagic disease.

54 the Filoviridae family associated with human hemorrhagic disease.

55 ve agent of Lassa fever (LF), an often-fatal hemorrhagic disease.

56 k of arterial and venous thrombosis and with hemorrhagic disorders.

57 are surgically excised if accessible, while hemorrhagic dural arteriovenous fistulas and distal/myco

58 of MEV infection.IMPORTANCE MEV causes fatal hemorrhagic enteritis in minks.

59 MEV), an autonomous parvovirus, causes acute hemorrhagic enteritis in minks.

60 ing severe diseases in dogs, including acute hemorrhagic enteritis, myocarditis, and cerebellar disea

61 IC(025): 3.97), central nervous system (CNS) hemorrhagic events (ROR: 3.7; 95% confidence interval: 3

62 0 years) clinical outcomes (death, ischemic, hemorrhagic events) following transcatheter PFO closure.

63 lly decreased the number of annual Argentine hemorrhagic fever (AHF) cases.

64 ns and is the etiological agent of Argentine hemorrhagic fever (AHF).

65 irus (MACV), the causative agent of Bolivian hemorrhagic fever (BHF), is a New World arenavirus that

66 laboratory tests available for Crimean-Congo hemorrhagic fever (CCHF) and their utility in diagnosis

67 stock following an outbreak of Crimean Congo hemorrhagic fever (CCHF) in Gujarat state, India.

68 Crimean-Congo hemorrhagic fever (CCHF) is a widely distributed, viral,

69 Crimean-Congo hemorrhagic fever (CCHF) is the most widely distributed

70 hort of patients with dengue fever or dengue hemorrhagic fever (DHF) (n = 166) and controls (n = 149)

71 ut, in severe cases, life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)

72 develop the life-threatening diseases dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

73 In some patients with dengue hemorrhagic fever (DHF), vascular pathology can become s

74 er dengue fever to severe disease, or dengue hemorrhagic fever (DHF).

75 ) arenavirus and causative agent of Bolivian hemorrhagic fever (HF).

76 ainst all of these viruses that cause lethal hemorrhagic fever (HF).

77 Lassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa.

78 ue damage consistent with the development of hemorrhagic fever and lymphopenia.

79 nnually and has the potential to cause fatal hemorrhagic fever and shock.

80 Lassa fever (LF) is a zoonotic viral hemorrhagic fever caused by Lassa virus (LASV), which is

81 A)-approved vaccines are available to combat hemorrhagic fever caused by mammarenavirus infections in

82 Severe and fatal SFTS presents as a hemorrhagic fever characterized by high viral load, unco

83 erent species, and some of them cause lethal hemorrhagic fever disease, this group of viruses has bee

84 ited therapeutic options to treat the deadly hemorrhagic fever diseases they cause.

85 sa virus (LASV), can cause severe and lethal hemorrhagic fever diseases with high mortality and morbi

86 amples from 70 patients with suspected Ebola hemorrhagic fever during a 2014 outbreak in Boende, Demo

87 African swine fever virus (ASFV) causes hemorrhagic fever in domestic pigs, presenting the bigge

88 rus (ASFV) causes incurable and often lethal hemorrhagic fever in domestic pigs.

89 a highly pathogenic virus that causes severe hemorrhagic fever in humans and is responsible for epide

90 contagious, severe and often lethal form of hemorrhagic fever in humans.

91 V is one of five known NWAs that cause viral hemorrhagic fever in humans.

92 family Filoviridae) cause outbreaks of viral hemorrhagic fever in sub-Saharan Africa.

93 Several mammarenaviruses can cause deadly hemorrhagic fever infections in humans, with limited pre

94 Argentine hemorrhagic fever is a potentially lethal disease that i

95 Crimean-Congo hemorrhagic fever is the most geographically widespread

96 A feature of all NWMs that cause viral hemorrhagic fever is the use of human transferrin recept

97 h disease (CMTD) in humans, acts by blocking hemorrhagic fever New World arenavirus (NWA) entry into

98 es life-threatening diseases, such as dengue hemorrhagic fever or dengue shock syndrome.

99 from classical dengue fever to severe dengue hemorrhagic fever or dengue shock syndrome; however, the

100 Ebola virus causes devastating hemorrhagic fever outbreaks for which no approved therap

101 rus (MARV) has caused outbreaks of filoviral hemorrhagic fever since its discovery in 1967.

102 In its most severe form, YF manifests as a hemorrhagic fever that causes severe damage to visceral

103 er (RVF) is an emerging, zoonotic, arboviral hemorrhagic fever threatening livestock and humans mainl

104 Crimean-Congo hemorrhagic fever virus (CCHFV) is a cause of severe hem

105 he viral life cycle.IMPORTANCE Crimean-Congo hemorrhagic fever virus (CCHFV) is a priority pathogen t

106 Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne Nairovir

107 Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne pathogen

108 Crimean-Congo hemorrhagic fever virus (CCHFV) is the causative agent o

109 Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne bunyavirus

110 A notable member is Crimean-Congo hemorrhagic fever virus (CCHFV), which is the most widel

111 Treatment of blood samples from hemorrhagic fever virus (HFV)-infected patients with 0.1

112 infected crab-eating macaques, while simian hemorrhagic fever virus (SHFV) causes lethal viral hemor

113 then crab-eating macaques with either simian hemorrhagic fever virus (SHFV) or Kibale red colobus vir

114 The nsp1beta of simian hemorrhagic fever virus (SHFV) was identified as a key f

115 eviously reported for the arterivirus Simian hemorrhagic fever virus (SHFV).

116 responses in control of acute Crimean-Congo hemorrhagic fever virus infection is largely unclear.

117 or zoonotic pathogens, such as Crimean Congo hemorrhagic fever virus, Babesia, Theileria, and Anaplas

118 member of the same subtype as Crimean-Congo hemorrhagic fever virus, responsible for fatal human dis

119 virales and closely related to Crimean-Congo hemorrhagic fever virus, which is responsible for severe

120 human pathogens in existence, Crimean-Congo hemorrhagic fever virus.

121 (LASV), two unrelated but highly pathogenic hemorrhagic fever viruses that have caused outbreaks in

122 gunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses.

123 the causative agent of Lassa fever, a viral hemorrhagic fever with a case fatality rate of approxima

124 is an ambisense RNA virus that causes severe hemorrhagic fever with a high fatality rate in humans in

125 s a tick-borne Nairovirus that causes severe hemorrhagic fever with a mortality rate of up to 30% in

126 pathogen that can cause severe outbreaks of hemorrhagic fever with high mortality rates.

127 Hantavirus infections cause hemorrhagic fever with renal syndrome (HFRS) and hantavi

128 humans, where they provoke diseases such as Hemorrhagic fever with Renal Syndrome (HFRS) and its mil

129 Puumala (PUUV) orthohantavirus causes hemorrhagic fever with renal syndrome (HFRS).

130 Puumala orthohantavirus (PUUV) causes hemorrhagic fever with renal syndrome (HFRS).

131 In humans, orthohantavirus infection causes hemorrhagic fever with renal syndrome or hantavirus card

132 the causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome and is ende

133 e of illness, including dengue fever, dengue hemorrhagic fever, and dengue shock syndrome.

134 rus (JUNV), the causative agent of Argentine hemorrhagic fever, demonstrating the feasibility of usin

135 veloped filamentous RNA virus causing severe hemorrhagic fever, enters cells by macropinocytosis and

136 uses (NWAs) can cause severe and often fatal hemorrhagic fever, for which preventive and therapeutic

137 EBOV causes hemorrhagic fever, organ damage, and shock culminating i

138 has been shown to protect against Argentine hemorrhagic fever-like disease in marmosets infected wit

139 s (JUNV), the etiological agent of Argentine hemorrhagic fever.

140 zoonotic pathogens capable of causing fatal hemorrhagic fever.

141 ct humans and non-human primates, and causes hemorrhagic fever.

142 gic fever virus (CCHFV) is a cause of severe hemorrhagic fever.

143 ked reduction in platelet counts, and dengue hemorrhagic fever.

144 uses responsible for dengue fever and dengue hemorrhagic fever.

145 ated with a cluster of human cases of severe hemorrhagic fever.

146 continent to cause epidemics of highly fatal hemorrhagic fever.

147 causative agents of dengue fever and dengue hemorrhagic fever.

148 hagic fever virus (SHFV) causes lethal viral hemorrhagic fever.

149 uated vaccine for the treatment of Argentine hemorrhagic fever.

150 Recent outbreaks of viral hemorrhagic fevers (VHFs), including Ebola virus disease

151 Hemorrhagic fevers caused by viruses were identified in

152 of vaccines and therapeutics to combat viral hemorrhagic fevers remains a top priority within the Imp

153 odent populations can cause life-threatening hemorrhagic fevers when they infect humans.

154 ing viral pathogens that cause encephalitis, hemorrhagic fevers, and meningitis.

155 e as experimental vaccines for several viral hemorrhagic fevers.

156 agnostic replacement for the ELISA for viral hemorrhagic fevers.

157 ttenuated vaccine candidates for other viral hemorrhagic fevers.

158 y more restrictive (lower median CCS) in the hemorrhagic group than in the nonhemorrhagic group (1 vs

159 luid (CSF) hypersecretion in a model of post-hemorrhagic hydrocephalus.

160 Iron overload occurs in many hemorrhagic injuries due to hemolysis and hemoglobin deg

161 ated prolonged survival of rats subjected to hemorrhagic injury (HI) when treated with DCA.

162 g neuroinflammatory responses accompanied by hemorrhagic lesions and neuronal impairment, which are l

163 s with variable enhancement, with associated hemorrhagic lesions in 11 of 37 patients (30%; 95% CI: 1

164 f patients (20 of 37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presenta

165 ile illness in humans, which can progress to hemorrhagic manifestations, multi-organ failure, and dea

166 h as ischemic infarct, hemorrhage, and acute hemorrhagic necrotizing encephalopathy.

167 We report a case of hemorrhagic occlusive retinal vasculitis (HORV) after pr

168 of presentation, diagnosis, and outcomes of hemorrhagic occlusive retinal vasculitis (HORV).

169 pathologic process such as CAA may result in hemorrhagic or ischemic brain lesions potentially throug

170 h and improves function when delivered after hemorrhagic or ischemic stroke.

171 was not associated with reduced ischemic and hemorrhagic outcomes.

172 O females are anovulatory and develop cystic hemorrhagic ovaries that are thought to be due to persis

173 adult mice displayed a more overt cystic and hemorrhagic phenotype when compared with ERalpha KO litt

174 ducing severe vasculitis, colitis and lethal hemorrhagic pneumonia in interferon gamma receptor-defic

175 ion was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined t

176 sma soluble TM may represent a biomarker for hemorrhagic risk in CCMs.

177 hemic: RR, 0.89 [95% CI, 0.81-0.99], P=0.03; hemorrhagic: RR, 0.60 [95% CI, 0.54-0.68], P<0.0001) wer

178 aining trout virulence determinants of viral hemorrhagic septicemia virus (VHSV) have not been succes

179 Viral hemorrhagic septicemia virus (VHSV), a fish rhabdovirus,

180 , 60 +/- 14 yr old) with septic shock (30%), hemorrhagic shock (15%), cardiogenic shock (20%), or no

181 organ injury and dysfunction associated with hemorrhagic shock (HS) in the rat.

182 organ injury and dysfunction associated with hemorrhagic shock (HS) in the rat.

183 polysaccharide(LPS)-induced shock (LPSS) and hemorrhagic shock (HS).

184 ere injury including major trauma, burns, or hemorrhagic shock (HS).

185 lled exosomes, secreted into ML after trauma/hemorrhagic shock (T/HS) have the potential to activate

186 nvestigated how alcohol intoxication impacts hemorrhagic shock and resuscitation-induced microvascula

187 cardiac output in an adult porcine model of hemorrhagic shock and resuscitation.

188 re designed in a mouse model of resuscitated hemorrhagic shock and tissue trauma (HS/T).

189 uce 30-day mortality in patients at risk for hemorrhagic shock compared with crystalloid only resusci

190 lso, 50% of massively transfused patients in hemorrhagic shock demonstrated SD physiology on admissio

191 Lungs from mice undergoing hemorrhagic shock exhibited a significant increase in mi

192 blood loss and attenuate the progression to hemorrhagic shock following severe trauma.

193 Hyperoxia during resuscitation from hemorrhagic shock in swine with preexisting coronary art

194 ease, and systemic inflammation after severe hemorrhagic shock in the absence of fluid resuscitation

195 short-term survival of rats following severe hemorrhagic shock in the absence of fluid resuscitation.

196 Fluid resuscitation following hemorrhagic shock is often problematic, with development

197 ts demonstrate that miR-19b was increased in hemorrhagic shock patients and in-vitro specifically bou

198 Hemorrhagic shock results in systemic injury to the endo

199 Patients with hemorrhagic shock should receive prehospital blood produ

200 Patients with hemorrhagic shock should receive prehospital blood produ

201 Hemorrhagic shock was induced in rats by withdrawing 60%

202 Severe hemorrhagic shock was induced in rats by withdrawing blo

203 tings such as myocardial infarction, stroke, hemorrhagic shock, and solid organ transplant are partic

204 its mortality in the primate model of severe hemorrhagic shock.

205 resuscitation strategy in an animal model of hemorrhagic shock.

206 nd improved brain perfusion following severe hemorrhagic shock.

207 e during life-threatening conditions such as hemorrhagic shock.

208 protocols are the mainstay of treatment for hemorrhagic shock; however, the exact RBC to fresh froze

209 4; P=0.008) and a nonsignificant increase in hemorrhagic stroke (0.8% versus 0.6%; HR, 1.38; 95% CI,

210 rson-years; p < 0.001) and the incidences of hemorrhagic stroke (1.21 vs. 4.19 events per 1000 person

211 I: 0.53, 1.34; P-trend = 0.44), and 0.75 for hemorrhagic stroke (95% CI: 0.32, 1.77; P-trend = 0.40).

212 0.73 [95% CI, 0.57-0.93]) without increasing hemorrhagic stroke (HR, 0.83 [95% CI, 0.42-1.65]).

213 chemic stroke (HR, 1.11 [1.02-1.21]) but not hemorrhagic stroke (HR, 1.02 [0.82-1.29]).

214 y aimed to investigate the long-term risk of hemorrhagic stroke (HS) in patients with infective endoc

215 oembolism (OR, 0.79 [95% CI, 0.67-0.93]) and hemorrhagic stroke (OR, 0.78 [95% CI, 0.62-0.98]).

216 6, 1.77]), while a negative association with hemorrhagic stroke also appeared within this subgroup.

217 r ischemic stroke, and 1.35 [1.13, 1.61] for hemorrhagic stroke among men, while among women higher a

218 ns for impairment of consciousness following hemorrhagic stroke and recovery at ICU discharge.

219 Furthermore, risk of hemorrhagic stroke did not depend on achieved LDL-C leve

220 and risk of any stroke, ischemic stroke, and hemorrhagic stroke during a mean follow-up interval of 1

221 ibrillation, and document the lowest rate of hemorrhagic stroke identified in this population.

222 sk factors and outcomes of each ischemic and hemorrhagic stroke in patients with venoarterial extraco

223 etween lower achieved LDL-C and incidence of hemorrhagic stroke in the alirocumab group.

224 Neonatal hemorrhagic stroke is more common than previously report

225 delivering MSCs intraventricularly in a rat hemorrhagic stroke model.

226 protects neurons, and improves behavior in a hemorrhagic stroke model.

227 is important to note that NAC did not worsen hemorrhagic stroke outcome, suggesting that it exerts th

228 f myocardial infarction, ischemic stroke, or hemorrhagic stroke over a period of 8 years.

229 ions, for 4 domains affected in ischemic and hemorrhagic stroke patients.

230 irocumab treatment at month 4 and subsequent hemorrhagic stroke was assessed.

231 The risk of nonfatal or fatal ischemic or hemorrhagic stroke was evaluated, stratified by baseline

232 Using autologous blood, hemorrhagic stroke was induced at specific coordinates i

233 Hemorrhagic stroke was significantly less than ischemic

234 t rates were higher when ischemic stroke and hemorrhagic stroke were present (76% and 86%, respective

235 roke/transient ischemic attack and 153 prior hemorrhagic stroke) and bleeding (318 prior major bleedi

236 ditioning protocol and all patients but one (hemorrhagic stroke) survived through 1 year of follow-up

237 with patients without a stroke (43+/-12% for hemorrhagic stroke, 57+/-9% for ischemic stroke, 51+/-11

238 ng death, all-cause stroke, ischemic stroke, hemorrhagic stroke, and bleeding hospitalizations in ESR

239 l reductions in major bleeding, particularly hemorrhagic stroke, and mortality.

240 e menopause and gestational hypertension for hemorrhagic stroke, and oophorectomy, HDP, preterm deliv

241 However, differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascul

242 Bleeding outcome was serious bleeding (hemorrhagic stroke, hospitalization for bleeding, transf

243 kely to be older, smokers, have a history of hemorrhagic stroke, hypothyroidism, and dementia, and le

244 n risk of ischemic stroke without increasing hemorrhagic stroke, irrespective of baseline LDL-C and o

245 risks (RR) of stroke and systemic embolism, hemorrhagic stroke, myocardial infarction, cardiovascula

246 and whether loci influence both ischemic and hemorrhagic stroke, remains unknown.

247 ogical disorders, including ischemic stroke, hemorrhagic stroke, traumatic brain injury, Alzheimer's

248 encephalomyelitis, meningitis, ischemic and hemorrhagic stroke, venous sinus thrombosis, and endothe

249 odifiable risk factors for both ischemic and hemorrhagic stroke, while hypertension, smoking, diet, a

250 emonstrated opposing effects on ischemic and hemorrhagic stroke.

251 stress in cancer, heat stress in plants, and hemorrhagic stroke.

252 ess the effect of alirocumab on ischemic and hemorrhagic stroke.

253 the mechanism and predictors of ischemic and hemorrhagic stroke.

254 cortical or vertebrobasilar, and ischemic or hemorrhagic stroke.

255 rebral circulation, resulting in ischemic or hemorrhagic stroke.

256 L-C levels and a potential increased risk of hemorrhagic stroke.

257 ndidate agents for this untreatable cause of hemorrhagic stroke.

258 any stroke: 166 of ischemic stroke and 55 of hemorrhagic stroke.

259 n of ischemic injury, and presumed perinatal hemorrhagic stroke.

260 ted with increased risk of stroke overall or hemorrhagic stroke.

261 associated factors, and outcomes of neonatal hemorrhagic stroke.

262 and 0.2% (95% CI = 0.1-0.3%, I(2) = 64%) for hemorrhagic stroke.

263 p = 0.02) were independently associated with hemorrhagic stroke.

264 ow promise for the treatment of ischemic and hemorrhagic stroke.

265 ll alive with 1 death on ECMO, attributed to hemorrhagic stroke.

266 d ischemic stroke and 229 (2.2%) experienced hemorrhagic stroke.

267 hat tend to rupture, increasing the risk for hemorrhagic stroke.

268 d 10,922 ischemic strokes, and 2492 and 2363 hemorrhagic strokes among men and women, respectively.

269 ortality rates remain high when ischemic and hemorrhagic strokes are present.

270 In total, 263 ischemic and 33 hemorrhagic strokes occurred.

271 MII), 65 strokes (40 ischemic strokes and 25 hemorrhagic strokes) occurred in 52 patients at a median

272 c stroke, 3 of which influenced ischemic and hemorrhagic subtypes under both TOAST and causative clas

273 rne bunyavirus, can cause a life-threatening hemorrhagic syndrome in humans but not in its animal hos

274 eriovenous malformations (AVM) in hereditary hemorrhagic telangiectasia (HHT) can necessitate liver t

275 Hereditary hemorrhagic telangiectasia (HHT) is a Mendelian disease

276 Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominan

277 o determine whether patients with hereditary hemorrhagic telangiectasia (HHT) who smoke tobacco are m

278 oposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic inv

279 Hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding dis

280 tion in an in vivo Smad4 model of hereditary hemorrhagic telangiectasia alleviated these vascular phe

281 o the inherited vascular disorder hereditary hemorrhagic telangiectasia characterized by local telang

282 Hereditary hemorrhagic telangiectasia is an autosomal dominant vasc

283 utic value for the alleviation of hereditary hemorrhagic telangiectasia symptoms, such as AVMs.

284 s in the gene encoding ALK1 cause hereditary hemorrhagic telangiectasia type 2, a rare genetic diseas

285 nstream effectors responsible for hereditary hemorrhagic telangiectasia-associated AVM formation are

286 ter embolization in patients with hereditary hemorrhagic telangiectasia.

287 poor outcomes (80.0% vs. 25.8%, P < 0.001), hemorrhagic transformation (32.5% vs. 9.6%, P = 0.01), a

288 ership, 47 [79.7%]; P = .49) and symptomatic hemorrhagic transformation (drip and ship, 2 [2.0%]; mot

289 poststroke neuroinflammation contributes to hemorrhagic transformation and progression of neurodegen

290 of stroke in the era of reperfusion therapy: hemorrhagic transformation and the disconnect between su

291 use was evident in 19 of the 51 cases of non-hemorrhagic transformation NHS (37%).

292 mary and secondary intracerebral hemorrhage, hemorrhagic transformation of ischemic injury, and presu

293 tiate anticoagulation, such as infarct size, hemorrhagic transformation, or high-risk features on ech

294 stributed between idiopathic, secondary, and hemorrhagic transformation.

295 of reperfusion therapy with t-PA by limiting hemorrhagic transformation.

296 emporal trends in acute stroke (ischemic and hemorrhagic)/transient ischemic attack incidence and in-

297 p, overall and by type of event (ischemic or hemorrhagic), using survival analyses and Cox proportion

298 ncluding device association, type of stroke (hemorrhagic versus ischemic), changing severity of impai

299 monary, renal, metabolic, cardiovascular and hemorrhagic, was associated with higher odds of death, w

300 ase (PLD) is rare, extremely challenging and hemorrhagic, without standard approach.